NA
RVPH

NewEdge Advisors’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

NewEdge Advisors’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,045
Closed -$58.1K – 4131
2025
Q1 		$58.1K Buy
+3,045
New +$95.7K ﹤0.01% 2499

Other funds holding RVPH

DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

NewEdge Advisors's RVPH Position: Q2 2025 in Review

NewEdge Advisors sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q2 2025, closing a stake of 3,045 shares — an estimated $58.1K sold.

NewEdge Advisors first reported a position in RVPH in Q1 2025 and held it in 1 quarter. The position peaked at $58.1K in Q1 2025. 46 funds tracked by Wall St. Rank hold RVPH as of Q2 2025.

  • NewEdge Advisors reported no remaining REVIVA PHARMA HLDGS INC position as of Q2 2025 after selling out during the quarter.
  • NewEdge Advisors sold 3,045 REVIVA PHARMA HLDGS INC shares in Q2 2025, an estimated $58.1K.
  • NewEdge Advisors first reported a position in REVIVA PHARMA HLDGS INC in Q1 2025 and held it in 1 quarter.
  • NewEdge Advisors's REVIVA PHARMA HLDGS INC position peaked at $58.1K in Q1 2025.
  • 46 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q2 2025.

Based on NewEdge Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.